We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Schedule an appointment today

Call to Schedule: 1-866-UH4-CARE
Cancer Research
Visit the Research & Education Institute

PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma

This study is currently closed to enrollment.

lady with scarf
AGE: 18 years and older
GENDER: All
TYPE: Biological Study (PVSRIPO, pembrolizumab)
HEALTHY PARTICIPANTS: No
CONDITION: Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, Brain Tumor

ISTR1320, A Phase 1, Open-label, Single-arm Study Evaluating the Safety and Tolerability of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients with Recurrent Glioblastoma (PVSRIPO CPI rGBM 101)

Study Purpose

The purpose of this study is to determine the tolerance, safety and efficacy of a single dose of PVSRIPO followed by pembrolizumab is in adults diagnosed with a recurrent glioblastoma (rGBM). PVSRIPO and Pembrolizumab are investigational (experimental) drugs. Pembrolizumab works by helping your immune system recognize and fight cancer cells.

Who Can Participate

Patients 18 years of age or older 18 years of age who have been histologically confirmed with recurrent, supratentorial glioblastoma; progression of primary glioblastoma or transformation from a lower grade to a higher grade of glioblastoma may be eligible for this study.

Study ID